The Latin American Society of Interventional Cardiology will once more say here at EuroPCR 2024, undoubtedly one of the most relevant international meetings in the field. In this context, a joint symposium will be held on Thursday 16 at 14.45 (UTC +2 – Paris time), in room 253. This session will discuss “State of the<a href="https://solaci.org/en/2024/04/25/solacipcr-joint-session-at-europcr-2024-see-you-in-paris-on-may-14-thru-17/" title="Read more" >...</a>
Patients with peripheral vascular disease often experience femoropopliteal compromise. It is estimated that approximately 50% of lesions in this area are chronic total occlusions (CTO). Even though success rate has improved for peripheral CTO treatments, long term clinical and technical outcomes have not been fully determined yet. Prior research has looked into stenting outcomes in<a href="https://solaci.org/en/2024/04/19/drug-coated-balloon-angioplasty-in-femoropopliteal-ctos-intraluminal-or-subintimal/" title="Read more" >...</a>
On the one hand, chronic peripheral vascular disease is on the rise. On the other, over the past 20 years, percutaneous coronary intervention (PCI) has gained considerable ground thanks to various new devices, replacing surgery as an alternative in most scenarios. Both strategies have shown similar results, but PCI has fewer complications and shorter hospital stays.<a href="https://solaci.org/en/2024/04/18/peripheral-vascular-disease-our-reality-in-latin-america-with-the-latam-solaci-peripheral-registry/" title="Read more" >...</a>
Severe persistent calcification of the coronary arteries has been associated with different factors, such as advanced age, hypertension, dyslipidemia, smoking, and kidney failure, among others, and continues to be one of the challenges to stent implantation because of it impact on device advancing, drug release and adequate positioning. Intravascular lithotripsy (IVL) is a technique that<a href="https://solaci.org/en/2024/04/05/lithotripsy-in-the-real-world-replica-epic-18-study/" title="Read more" >...</a>
The presence of calcification in coronary arteries (CAC) remains a challenge for the percutaneous treatment of these lesions. Several studies have established the link between CAC and poor long term results. Intravascular lithotripsy (IVL) has surged as a tool to induce calcified plaque fracture. Even though studies on this strategy are not randomized, they have<a href="https://solaci.org/en/2024/03/13/use-of-ivl-in-calcified-coronary-lesions-in-a-real-world-population/" title="Read more" >...</a>
A lesion ≥50% in the left main coronary artery (LMCA) is considered severe, according to various scientific societies, regardless of the presence of symptoms or ischemia, due to the extent of myocardium at risk. In such cases, revascularization is indicated. In many patients, lesions in this section of the coronary artery have severe calcification, which<a href="https://solaci.org/en/2024/03/13/lithotripsy-in-the-left-main-coronary-artery/" title="Read more" >...</a>
Over time, percutaneous coronary intervention (PCI) with drug coated balloons (DCB) have been shown more beneficial than conventional PCI. However, in many cases, stenting is required to treat suboptimal results. Even though several studies have looked into this scenario, long term durability still calls for research. This was a 5 year thorough analysis of the<a href="https://solaci.org/en/2024/03/09/in-pact-outcomes-at-5-years/" title="Read more" >...</a>
Patients suffering from immune-mediated chronic inflammatory disease (CID) face a high risk of developing heart disease, including aortic valve disease. Inflammatory vascular disease when triggered by an autoimmune condition, can prompt a harmful response leading to valve degeneration, with increased calcification and fibrosis, and the associated progression of stenosis, failure or both. Prior research has<a href="https://solaci.org/en/2024/03/04/post-tavr-long-term-outcomes-in-patients-with-chronic-inflammatory-disease/" title="Read more" >...</a>
The Left main coronary artery supplies circulation to roughly 70% of myocardium, and left main disease requires a high risk intervention with significant impact on patient prognosis. The current guidelines have set the threshold for intervention in LM disease at ≥50% stenosis, irrespective of the presence of symptoms or ischemic burden. LM calcification is an<a href="https://solaci.org/en/2024/02/27/use-of-intravascular-lithotripsy-in-left-main/" title="Read more" >...</a>
Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery. Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the<a href="https://solaci.org/en/2024/02/01/promising-results-of-transcatheter-mitral-valve-replacement-in-bioprosthesis-failure/" title="Read more" >...</a>